GlassScriptPhysician profile
Carey D Crill
NPI 1457530693
$19,168.15
in general payments reported to CMS, 2019-2025
24 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,005 · 2022: $941 · 2023: $10K · 2024: $4,419 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,588 · Food and Beverage: $2,879 · Travel and Lodging: $1,781 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,588.00 |
| Food and Beverage | $2,878.56 |
| Travel and Lodging | $1,780.88 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $975.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $12,061.46 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $1,577.94 | 2021-2025 | Spravato, Invega Sustenna |
| Neuronetics, INC. | $1,371.88 | 2021 | |
| Abbvie INC. | $975.25 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $599.75 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $406.93 | 2021-2025 | Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $270.32 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $243.39 | 2021-2024 | Uzedy, Austedo Xr |
| Lundbeck LLC | $236.75 | 2021-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $229.80 | 2021-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $220.40 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $173.92 | 2021-2023 | Trintellix |
| Corium, LLC | $148.32 | 2022-2025 | Azstarys |
| Eisai INC. | $119.06 | 2021 | |
| Vanda Pharmaceuticals INC. | $114.87 | 2021-2023 | Hetlioz, Fanapt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $98.09 | 2021-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $94.82 | 2021-2023 | Belsomra |
| Sunovion Pharmaceuticals INC. | $80.24 | 2021 | |
| Ironshore Pharmaceuticals INC. | $34.73 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $33.66 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $31.05 | 2024 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.48 | 2024 | Rexulti |
| Indivior INC. | $14.43 | 2022 | |
| Adlon Therapeutics L.P. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carey Crill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.